MedPath

Calfactant

Generic Name
Calfactant
Brand Names
Infasurf
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
183325-78-2
Unique Ingredient Identifier
Q4K217VGA9
Background

Calfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. It is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. Each milliliter of calfactant contains 35mg of phospholipids (including 26 mg phosphatidylcholine of which 16 mg is disaturated phosphatidylcholine) and 0.65mg of proteins including surfactant-associated proteins B and C.

Calfactant is approved for use in the United States of America. It is used to prevent or treat respiratory distress syndrome in premature infants with lung surfactant deficiency. Calfactant has been shown to decrease the incidence of respiratory distress syndrome, mortality due to respiratory distress syndrome, and air leaks associated with respiratory distress syndrome in clinical trials. It adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant.

Indication

用于预防和治疗早产儿呼吸窘迫综合征(RDS)。

Associated Conditions
Respiratory Distress Syndrome
Associated Therapies
-
targetedonc.com
·

Phase 1b/2 Study of BXQ-350 in Metastatic Colorectal Cancer Completes Enrollment

The ASIST study (NCT05322590) has completed enrollment for its open-label phase 1b/2 portion, evaluating BXQ-350 plus standard of care (mFOLFOX7 and bevacizumab) for newly diagnosed metastatic colorectal cancer. BXQ-350, a first-in-class biologic, aims to reduce chemotherapy-induced peripheral neuropathy. The study includes stages to determine the optimal dose and assess safety and efficacy, with completion expected in April 2029.

Well Prepared to Tackle New Pandemics

WACKER and CordenPharma secured pandemic-preparedness contracts in 2022 to produce mRNA vaccines in Germany, covering the entire process chain from plasmid DNA to sterile filling. They aim to be fully operational by Q2 2024, with a capacity to produce 80 million vaccine units annually. The project involves significant expansion at WACKER's Halle site and CordenPharma's sites in Frankfurt, Chenôve, and Caponago. Both companies emphasize flexibility and readiness, with a focus on rapid deployment and maintaining standby capacity for vaccine production.
© Copyright 2025. All Rights Reserved by MedPath